SavedAdd your journal

Journals / Journal of Medical Topics and Updates / 2022 / Cilt: 1 - Sayı: 1

Treatment-emergent central sleep apnea (Te-Csa)

Tedaviyle ortaya çıkan santral uyku apnesi (Te-Csa)

Ayşegül ALTINTOP GEÇKİL
Pages
28–31
Publication Date
2022-04-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recognition and assessment of the TE-CSA course and initiation of targeted management for TE-CSA may improve symptom control and quality of life in patients with sleep-disordered breathing.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Treatment-emergent central sleep apnea (TE-CSA) is a condition in which central sleep apnea (CSA) occurs in patients treated with obstructive sleep apnea (OSA) in a diagnostic part of the sleep test, while the obstructive apnea is controlled during the treatment process.
📊
Key Findings & Data:TE-CSA is seen in approximately 5-10% of OSA patients.
💡
Conclusion & Impact:Recognition and assessment of the TE-CSA course and initiation of targeted management for TE-CSA may improve symptom control and quality of life in patients with sleep-disordered breathing.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:TE-CSA · BPAP · ASV

Abstract

Treatment-emergent central sleep apnea (TE-CSA) is a condition in which central sleep apnea (CSA) occurs in patients treated with obstructive sleep apnea (OSA) in a diagnostic part of the sleep test, while the obstructive apnea is controlled during the treatment process. TE-CSA is seen in approximately 5-10% of OSA patients. The prevalence of TE-CSA is higher in patients with cardiac comorbidities such as heart failure. In patients with TE-CSA, the use of positive airway pressure (PAP) therapy and treatment compliance were found to be poor compared to patients with classical OSA, unless appropriate therapy was chosen. Recognition and assessment of the TE-CSA course and initiation of targeted management for TE-CSA may improve symptom control and quality of life in patients with sleep-disordered breathing.

Özet

Tedaviyle ortaya çıkan santral uyku apnesi (TE-CSA), obstrüktif uyku apne (OSA) tanısı ile tedavi başlanan hastalarda, tedavi sürecinde obstrüktif apneler kontrol altına alınmasına rağmen, santral uyku apnesinin (CSA) ortaya çıkmasıdır. OSA hastalarının yaklaşık %2-20’sinde TE-CSA görülmekte olup TE-CSA prevalansı kardiyak komorbiditeleri olan hastalarda daha yüksektir. TE-CSA hastalarında, uygun tedavi seçilmediği takdirde, klasik OSA'lı hastalara kıyasla pozitif havayolu basınç (PAP) tedavisi kullanımının ve tedavi uyumunun zayıf olduğu saptanmıştır. TE-CSA tanılı hastaların değerlendirilmesi ve uygun tedavilerin başlanması, uykuda solunum bozukluğu olan hastalarda, semptom kontrolünü ve yaşam kalitesini iyileştirebilir.

🔖

Cite This Article

GEÇKİL, A. A. (2022). Treatment-emergent central sleep apnea (Te-Csa). Journal of Medical Topics and Updates, Cilt: 1 - Sayı: 1, 28–31. https://ajindex.com/articles/853597

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Allam, J.S., Olson, E.J., Gay, P.C. & Morgenthaler, T.I. (2007). Efficacy of adaptive servo ventilation in treatment of complex and central sleep apnea syndromes. Chest., 132, 1839–46.
  2. American Academy of Sleep Medicine. (2014).
  3. Andreas, S., Weidel, K., Hagenah, G. & Heindl, S. (1998). Treatment of Cheyne-Stokes respiration with nasal oxygen and carbon dioxide. Eur Respir J., 12, 414–9.
  4. Cassel, W., Canisius, S., Becker, H.F., Leistner, S., Ploch, T., Jerrentrup, A., Vogelmeier, C., … & Heitmann, J. (2011). A prospective polysomnographic study on the evolution of complex sleep apnoea. Eur Respir J., 38, 329–37.
  5. Cowie, M.R., Woehrle, H., Wegscheider, K., Angermann, C., d’Ortho, M., Erdmann, E., Levy, P., … & Teschler, H. (2015). Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med., 373, 1095–105.
  6. Eckert D.J., Owens R.L., Kehlmann G.B., Wellman, A., Rahangdale, S., Yim-Yeh, S., White D.P., …& Malhotra, A. (2011). Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with alow arousal threshold. Clin Sci., 120, 505–14.
  7. Edwards, B.A., Sands, S.A., Eckert, D.J., White, D.P., Butler, J.P., Owens, R.L., Malhotra & Wellman, A.A. (2012). Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea. J Physiol., 590, 1199–211.
  8. Eskandari, D., Zou, D., Grote, L., Hoff, E. & Hedner, J. (2018). Acetazolamide reduces blood pressure and sleep-disordered breathing in patients with hypertension and obstructive sleep apnea: a randomized controlled trial. J Clin Sleep Med., 14, 309–17.
  9. Heider, K., Arzt, M., Lerzer, C., Kolb, L., Pfeifer, M., Maier, L.S., Gfüllner, F. & Malfertheiner, M.V. (2018). et al. Adaptive servo-ventilation and sleep quality in treatment emergent central sleep apnea and central sleep apnea in patients with heart disease and preserved ejection fraction. Clin Res Cardiol., 107, 421–9.
  10. Javaheri, S., Smith, J. & Chung, E. (2009). The prevalence and natural history of complex sleep apnea. J Clin Sleep Med., 5, 205–11.
  11. Khayat, R.N., Xie, A., Patel, A.K., Kaminski, A. & Skatrud, J.B. (2003). Cardiorespiratory effects of added dead space in patients with heart failure and central sleep apnea. Chest., 123, 1551–60.
  12. Kuzniar, T.J. & Morgenthaler, T.I. (2012). Treatment of complex sleep apnea syndrome. Chest, 142, 1049–57.
  13. Kuzniar, T.J., Kasibowska-Kuzniar, K., Ray, D.W. & Freedom,T. (2013). Clinical heterogen